Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?
adiponectin
cardiovascular complications
epigenetic mechanisms
inflammation
obesity
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2021
accepted:
22
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
In obesity, several epigenetic modifications, including histones remodeling, DNA methylation, and microRNAs, could accumulate and determine increased expression of inflammatory molecules, the adipokines, that in turn might induce or accelerate the onset and development of cardiovascular and metabolic disorders. In order to better clarify the potential epigenetic mechanisms underlying the modulation of the inflammatory response by adipokines, the DNA methylation profile in peripheral leukocytes of the promoter region of IL-6 and NF-kB genes and plasma miRNA-21 levels were evaluated in 356 healthy subjects, using quantitative pyrosequencing-based analysis, and correlated with plasma adiponectin levels, body fat content and the primary pro-inflammatory markers. In addition, correlation analysis of DNA methylation profiles and miRNA-21 plasma levels with intima-media thickness (IMT), a surrogate marker for early atherosclerosis, left ventricular mass (LVM), left ventricular ejection fraction (LVEF), and cardiac performance index (MPI) was also performed to evaluate any potential clinical implication in terms of cardiovascular outcome. Results achieved confirmed the role of epigenetics in the obesity-related cardiovascular complications and firstly supported the potential role of plasma miRNA-21 and IL-6 and NF-kB DNA methylation changes in nucleated blood cells as potential biomarkers for predicting cardiovascular risk in obesity. Furthermore, our results, showing a role of adiponectin in preventing epigenetic modification induced by increased adipose tissue content in obese subjects, provide new evidence of an additional mechanism underlying the anti-inflammatory properties and the cardiovascular benefits of adiponectin. The exact mechanisms underlying the obesity-related epigenetic modifications found in the blood cells and whether similar epigenetic changes reflect adipose and myocardial tissue modifications need to be further investigated in future experiments.
Identifiants
pubmed: 34869683
doi: 10.3389/fcvm.2021.768026
pmc: PMC8639875
doi:
Types de publication
Journal Article
Langues
eng
Pagination
768026Informations de copyright
Copyright © 2021 Fontanella, Scisciola, Rizzo, Surina, Sardu, Marfella, Paolisso and Barbieri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Epigenetics. 2019 May;14(5):421-444
pubmed: 30915894
Front Physiol. 2018 Aug 21;9:1030
pubmed: 30246793
Clin Chim Acta. 2007 May 1;380(1-2):24-30
pubmed: 17343838
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Biomark Res. 2021 Mar 12;9(1):18
pubmed: 33712063
J Atheroscler Thromb. 2011;18(5):351-8
pubmed: 21427505
Endocrinology. 2012 Nov;153(11):5285-96
pubmed: 23015294
Sci Rep. 2017 Oct 30;7(1):14349
pubmed: 29084944
Circulation. 1999 Dec 21-28;100(25):2473-6
pubmed: 10604883
Epigenetics. 2013 May;8(5):522-33
pubmed: 23644594
Mol Med Rep. 2017 Aug;16(2):2254-2258
pubmed: 28627656
FEBS Lett. 2013 May 21;587(10):1556-61
pubmed: 23597671
Lancet. 2014 Jun 7;383(9933):1990-8
pubmed: 24630777
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
PLoS One. 2013;8(3):e57652
pubmed: 23469214
FASEB J. 2020 Dec;34(12):16489-16503
pubmed: 33090591
Cancer Res. 2015 Sep 15;75(18):3692-5
pubmed: 26337909
Science. 2020 Jan 24;367(6476):388-392
pubmed: 31974244
J Cell Physiol. 2012 Jan;227(1):183-93
pubmed: 21381024
J Am Coll Cardiol. 1992 Nov 1;20(5):1251-60
pubmed: 1401629
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Epigenetics. 2021 Feb 8;:1-18
pubmed: 33550919
Twin Res Hum Genet. 2014 Jun;17(3):183-91
pubmed: 24735745
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Front Endocrinol (Lausanne). 2020 Oct 06;11:563816
pubmed: 33123088
Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R145-51
pubmed: 17428894
Nat Rev Genet. 2012 Oct;13(10):679-92
pubmed: 22945394
Methods Mol Biol. 2018;1856:269-282
pubmed: 30178258
J Mol Cell Biol. 2016 Apr;8(2):93-100
pubmed: 26993047
Genome Biol. 2016 Dec 12;17(1):255
pubmed: 27955697
Nat Rev Drug Discov. 2013 Nov;12(11):847-65
pubmed: 24172333
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059381
AIMS Genet. 2019 Aug 1;6(3):36-45
pubmed: 31663031
Eur J Med Res. 2010 Nov 4;15 Suppl 2:120-2
pubmed: 21147638
Front Immunol. 2019 Apr 17;10:799
pubmed: 31057539
Atherosclerosis. 2017 Aug;263:325-333
pubmed: 28577936
Arthritis Rheum. 2008 Sep;58(9):2686-93
pubmed: 18759290
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Front Immunol. 2018 Jun 25;9:1377
pubmed: 29988529
Circulation. 2000 Sep 12;102(11):1296-301
pubmed: 10982546
Epigenetics. 2012 Jun 1;7(6):606-14
pubmed: 22531363
Diabetes. 2006 Jun;55(6):1840-6
pubmed: 16731851
Clin Sci (Lond). 2019 Jan 3;133(1):23-40
pubmed: 30606812